OptiNose said today that it closed a $37 million Series D round led by Fidelity Management and Research Company. Avista Capital Partners, Entrepreneurs Fund and other current investors also contributed to the round. The Yardley, Penn.-based company said it plans to use the newly-acquired funds to support commercial development of its lead product candidate, OPN-375, […]
Funding Roundup
DexCom prices $350m debt offering
Dexcom Inc. (NSDQ:DXCM) yesterday priced a $350 million debt offering, adding $50 million to the private placement it expects to close May 12. The offering, of 0.75% convertible senior notes, mature in May 2022 and can be redeemed for DXCM stock in February of that year. San Diego-based DexCom said the conversion rate is about 10.1 […]
Visunex Medical raises $20m Series B for PanoCam neonate eye scanners
Visunex Medical Systems said last week that it raised a $20 million Series B round for its PanoCam line of neonatal eye imaging systems. Fremont, Calif.-based Visunex said the PanoCam line includes the LT and Pro wireless systems and a 3rd system set to debut in June. “The interest in the medical investment community to be part of this funding […]
Advanced Cardiac Therapies lands $45m round led by new PE shop Ajax Health
Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Therapeutics and the next-generation ablation catheter it’s developing. Earlier today the private equity giants launched tapped Spirox chairman & CEO Duke Rohlen to lead Ajax Health. Rohlen, the former president of FoxHollow Technologies and the founder & former chief executive of […]
Private equity shops form medical device portfolio management company
Private equity giants KKR and Aisling Capital said today that they’re launching a company to manage their portfolio of medical device companies called Ajax Health, tapping Spirox chairman & CEO Duke Rohlen to lead it. Rohlen is the former president of FoxHollow Technologies and the founder & former chief executive of CV Ingenuity. “There is a significant […]
Magenta raises $50m, inks partnership with Novartis for stem cell transplant drugs
Magenta Therapeutics said today that it closed a $50 million Series B round and licensed a clinical-stage program from Novartis (NYSE:NVS) to advance its stem cell transplantation platform. The company also inked a partnership deal with Be The Match BioTherapies. Google’s venture arm, GV, led the financing round and was joined by existing investors, including […]
Lyndra gets boost for drug delivery platform from U.S. allergy institute
Lyndra said today that it won a 5-year grant from the National Institute of Allergy and Infectious Diseases, a branch of the National Institutes of Health. The grant is slated to support the formulation and preclinical development of a once-weekly oral HIV treatment. The Watertown, Mass.-based company makes use of a sustained-release technology developed by Robert […]
Axonics raises another $15m for U.S. sacral neurostim trial
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome. The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C […]
Savara inks $15m loan agreement
Savara (NSDQ:SVRA) said today that it inked a $15 million loan agreement with Silicon Valley Bank. According to the deal, Savara can draw $7.5 million from the $15 million debt facility immediately. The company said it plans to use its newly-acquired capital to repay the pre-merger debt of $3.7 million it owes to Hercules Technology […]
Reva plans $40m convertible note offering
Reva Medical (ASX:RVA) said yesterday that it’s planning a $40 million convertible note offering with several institutional and 1 undisclosed corporate investor to fund the company’s ongoing needs, including the clinical development of its Fantom sirolimus-eluting bioresorbable coronary scaffold. Upon issuance of the convertible notes, the company is slated to receive $32.5 in net cash […]
DelMar closes $9m public offering
DelMar Pharmaceuticals (NSDQ:DMPI) closed its $9 million public offering today. Earlier this week, the company priced 2.8 million shares and warrants to purchase an aggregate of 2.1 million shares of common stock at $3.25 apiece. The offering’s warrants have an exercise price of $3.50 per share and have an term of exercise of 5 years, according to […]